盐酸氮卓斯汀/丙酸氟替卡松鼻用制剂在过敏性鼻炎治疗中的作用。
A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis.
作者信息
Ridolo Erminia, Montagni Marcello, Melli Valerie, Bonzano Laura, Incorvaia Cristoforo, Canonica Giorgio Walter
机构信息
Department of Clinical & Experimental Medicine, University of Parma, Parma, Italy.
Pulmonary Rehabilitation Unit, ICP Hospital, Milan, Italy.
出版信息
Ther Deliv. 2015;6(6):653-9. doi: 10.4155/tde.15.7. Epub 2015 Apr 27.
Rhinitis is a very common disease and represents a health problem for both children and adults globally. Rhinitis can be allergic or occur without any IgE-mediated sensitization to aeroallergens. Common symptoms include nasal congestion, postnasal drainage, nasal itching, rhinorrhea and sneezing. The most effective drugs for the treatment of rhinitis are antihistamines and topical glucocorticoids. MP29-02 (Dymista(®)) is a novel intranasal formulation combining the second-generation antihistamine, azelastine hydrochloride, with fluticasone propionate in a single device that has recently been developed. Here, we review the efficacy and safety profile of this intranasal formulation in the treatment of allergic and nonallergic rhinitis.
鼻炎是一种非常常见的疾病，在全球范围内对儿童和成人来说都是一个健康问题。鼻炎可以是过敏性的，也可以在没有任何对气传变应原的IgE介导致敏的情况下发生。常见症状包括鼻塞、鼻后滴漏、鼻痒、流涕和打喷嚏。治疗鼻炎最有效的药物是抗组胺药和局部糖皮质激素。MP29-02（Dymista(®)）是一种新型鼻内制剂，它将第二代抗组胺药盐酸氮卓斯汀与丙酸氟替卡松组合在一个最近开发的单一装置中。在此，我们综述了这种鼻内制剂在治疗过敏性和非过敏性鼻炎方面的疗效和安全性。
Zotero 插件